Do analysts rate LYRA or GCTK?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LYRA or GCTK more profitable?

GlucoTrack has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -5,491.17%. GlucoTrack's return on equity of -581.98% beat Lyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lyra Therapeutics -5,491.17% -1,010.91% -58.92% GlucoTrack N/A -581.98% -220.10%

Do analysts recommend LYRA or AMIX?

Autonomix Medical has a consensus target price of $42.00, suggesting a potential upside of 879.02%. Given Autonomix Medical's stronger consensus rating and higher probable upside, analysts plainly believe Autonomix Medical is more favorable than Lyra Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Autonomix Medical 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend FEED or LYRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts recommend LYRA or TNON?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Tenon Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate LYRA or BBLG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Lyra Therapeutics (LYRA) Competitors

$0.52 0.00 (0.00%)

As of 07/20/2026

Compare

LYRA vs. GCTK, AMIX, FEED, TNON, and BBLG

Should you buy Lyra Therapeutics stock or one of its competitors? MarketBeat compares Lyra Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lyra Therapeutics include GlucoTrack (GCTK), Autonomix Medical (AMIX), Nanovibronix (FEED), Tenon Medical (TNON), and Bone Biologics (BBLG). These companies are all part of the "medical equipment" industry.

How does Lyra Therapeutics compare to GlucoTrack?

Lyra Therapeutics (NASDAQ:LYRA) and GlucoTrack (NASDAQ:GCTK) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

GlucoTrack has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -5,491.17%. GlucoTrack's return on equity of -581.98% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%
GlucoTrack	N/A	-581.98%	-220.10%

95.6% of Lyra Therapeutics shares are owned by institutional investors. Comparatively, 10.9% of GlucoTrack shares are owned by institutional investors. 3.3% of Lyra Therapeutics shares are owned by insiders. Comparatively, 2.2% of GlucoTrack shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

GlucoTrack has lower revenue, but higher earnings than Lyra Therapeutics. Lyra Therapeutics is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyra Therapeutics	$600K	1.54	-$93.43M	-$19.15	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A

In the previous week, GlucoTrack had 9 more articles in the media than Lyra Therapeutics. MarketBeat recorded 9 mentions for GlucoTrack and 0 mentions for Lyra Therapeutics. GlucoTrack's average media sentiment score of 0.14 beat Lyra Therapeutics' score of 0.00 indicating that GlucoTrack is being referred to more favorably in the news media.

Company	Overall Sentiment
Lyra Therapeutics	Neutral
GlucoTrack	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lyra Therapeutics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

Summary

GlucoTrack beats Lyra Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Lyra Therapeutics compare to Autonomix Medical?

Lyra Therapeutics (NASDAQ:LYRA) and Autonomix Medical (NASDAQ:AMIX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

95.6% of Lyra Therapeutics shares are held by institutional investors. Comparatively, 10.8% of Autonomix Medical shares are held by institutional investors. 3.3% of Lyra Therapeutics shares are held by company insiders. Comparatively, 6.2% of Autonomix Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Lyra Therapeutics has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Autonomix Medical has a beta of -1.32, indicating that its share price is 232% less volatile than the broader market.

Autonomix Medical has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -5,491.17%. Autonomix Medical's return on equity of -239.36% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%
Autonomix Medical	N/A	-239.36%	-192.46%

Autonomix Medical has lower revenue, but higher earnings than Lyra Therapeutics. Autonomix Medical is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyra Therapeutics	$600K	1.54	-$93.43M	-$19.15	N/A
Autonomix Medical	N/A	N/A	-$16.72M	-$74.58	N/A

In the previous week, Autonomix Medical had 2 more articles in the media than Lyra Therapeutics. MarketBeat recorded 2 mentions for Autonomix Medical and 0 mentions for Lyra Therapeutics. Autonomix Medical's average media sentiment score of 0.99 beat Lyra Therapeutics' score of 0.00 indicating that Autonomix Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Lyra Therapeutics	Neutral
Autonomix Medical	Positive

Autonomix Medical has a consensus target price of $42.00, suggesting a potential upside of 879.02%. Given Autonomix Medical's stronger consensus rating and higher probable upside, analysts plainly believe Autonomix Medical is more favorable than Lyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Autonomix Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Autonomix Medical beats Lyra Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Lyra Therapeutics compare to Nanovibronix?

Nanovibronix (NASDAQ:FEED) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

16.4% of Nanovibronix shares are owned by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are owned by institutional investors. 5.2% of Nanovibronix shares are owned by insiders. Comparatively, 3.3% of Lyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nanovibronix has higher revenue and earnings than Lyra Therapeutics. Nanovibronix is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanovibronix	$2.55M	0.85	-$18.18M	-$8.82	N/A
Lyra Therapeutics	$600K	1.54	-$93.43M	-$19.15	N/A

Nanovibronix has a net margin of -923.20% compared to Lyra Therapeutics' net margin of -5,491.17%. Nanovibronix's return on equity of -54.25% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-923.20%	-54.25%	-43.10%
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%

In the previous week, Nanovibronix had 1 more articles in the media than Lyra Therapeutics. MarketBeat recorded 1 mentions for Nanovibronix and 0 mentions for Lyra Therapeutics. Nanovibronix's average media sentiment score of 0.00 equaled Lyra Therapeutics'average media sentiment score.

Company	Overall Sentiment
Nanovibronix	Neutral
Lyra Therapeutics	Neutral

Nanovibronix has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market. Comparatively, Lyra Therapeutics has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

Summary

Nanovibronix beats Lyra Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Lyra Therapeutics compare to Tenon Medical?

Lyra Therapeutics (NASDAQ:LYRA) and Tenon Medical (NASDAQ:TNON) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Tenon Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Tenon Medical has higher revenue and earnings than Lyra Therapeutics. Tenon Medical is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyra Therapeutics	$600K	1.54	-$93.43M	-$19.15	N/A
Tenon Medical	$3.94M	0.61	-$12.56M	-$1.29	N/A

Lyra Therapeutics has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Tenon Medical has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market.

Tenon Medical has a net margin of -270.09% compared to Lyra Therapeutics' net margin of -5,491.17%. Tenon Medical's return on equity of -907.60% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%
Tenon Medical	-270.09%	-907.60%	-110.17%

In the previous week, Tenon Medical had 2 more articles in the media than Lyra Therapeutics. MarketBeat recorded 2 mentions for Tenon Medical and 0 mentions for Lyra Therapeutics. Lyra Therapeutics' average media sentiment score of 0.00 equaled Tenon Medical'saverage media sentiment score.

Company	Overall Sentiment
Lyra Therapeutics	Neutral
Tenon Medical	Neutral

95.6% of Lyra Therapeutics shares are held by institutional investors. Comparatively, 22.7% of Tenon Medical shares are held by institutional investors. 3.3% of Lyra Therapeutics shares are held by insiders. Comparatively, 17.7% of Tenon Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Tenon Medical beats Lyra Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Lyra Therapeutics compare to Bone Biologics?

Lyra Therapeutics (NASDAQ:LYRA) and Bone Biologics (NASDAQ:BBLG) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Bone Biologics has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -5,491.17%. Bone Biologics' return on equity of -50.47% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%
Bone Biologics	N/A	-50.47%	-47.40%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Lyra Therapeutics' average media sentiment score of 0.00 equaled Bone Biologics'average media sentiment score.

Company	Overall Sentiment
Lyra Therapeutics	Neutral
Bone Biologics	Neutral

Lyra Therapeutics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

95.6% of Lyra Therapeutics shares are owned by institutional investors. Comparatively, 34.3% of Bone Biologics shares are owned by institutional investors. 3.3% of Lyra Therapeutics shares are owned by company insiders. Comparatively, 5.6% of Bone Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Bone Biologics has lower revenue, but higher earnings than Lyra Therapeutics. Bone Biologics is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyra Therapeutics	$600K	1.54	-$93.43M	-$19.15	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$2.27	N/A

Summary

Bone Biologics beats Lyra Therapeutics on 7 of the 10 factors compared between the two stocks.

Get Lyra Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LYRA vs. The Competition

Export

Metric	Lyra Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$923K	$3.09B	$6.81B	$12.41B
Dividend Yield	N/A	2.05%	2.67%	9.39%
P/E Ratio	-0.02	20.22	27.00	24.19
Price / Sales	1.54	340.55	517.32	92.93
Price / Cash	N/A	27.11	26.68	47.25
Price / Book	0.06	4.28	10.67	6.26
Net Income	-$93.43M	$65.94M	$3.60B	$331.76M
7 Day Performance	38.93%	-1.40%	-0.37%	-1.10%
1 Month Performance	-23.53%	0.22%	1.80%	-1.29%
1 Year Performance	-93.62%	17.79%	25.50%	18.84%

Lyra Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LYRA Lyra Therapeutics	N/A	$0.52 flat	N/A	-93.4%	$923K	$600K	N/A	50	Gap Up
GCTK GlucoTrack	0.4245 of 5 stars	$0.52 +12.8%	N/A	-93.0%	$3.26M	N/A	N/A	5	Analyst Downgrade
AMIX Autonomix Medical	3.5514 of 5 stars	$5.38 -6.4%	$42.00 +680.7%	-87.3%	$2.91M	N/A	N/A	1
FEED Nanovibronix	0.9221 of 5 stars	$0.47 +2.9%	N/A	N/A	$2.87M	$2.55M	N/A	20
TNON Tenon Medical	0.3677 of 5 stars	$0.20 -7.9%	N/A	-80.2%	$2.33M	$3.94M	N/A	8	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LYRA) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lyra Therapeutics (LYRA) Competitors

LYRA vs. GCTK, AMIX, FEED, TNON, and BBLG

How does Lyra Therapeutics compare to GlucoTrack?

Summary

How does Lyra Therapeutics compare to Autonomix Medical?

Summary

How does Lyra Therapeutics compare to Nanovibronix?

Summary

How does Lyra Therapeutics compare to Tenon Medical?

Summary

How does Lyra Therapeutics compare to Bone Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYRA vs. The Competition

Lyra Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lyra Therapeutics (LYRA) Competitors

LYRA vs. GCTK, AMIX, FEED, TNON, and BBLG

How does Lyra Therapeutics compare to GlucoTrack?

Is LYRA or GCTK more profitable?

Do insiders & institutionals believe in LYRA or GCTK?

Which has preferable earnings & valuation, LYRA or GCTK?

Does the media favor LYRA or GCTK?

Do analysts rate LYRA or GCTK?

Which has more risk & volatility, LYRA or GCTK?

Summary

How does Lyra Therapeutics compare to Autonomix Medical?

Do institutionals and insiders hold more shares of LYRA or AMIX?

Which has more volatility & risk, LYRA or AMIX?

Is LYRA or AMIX more profitable?

Which has better valuation and earnings, LYRA or AMIX?

Does the media favor LYRA or AMIX?

Do analysts recommend LYRA or AMIX?

Summary

How does Lyra Therapeutics compare to Nanovibronix?

Do analysts recommend FEED or LYRA?

Do insiders & institutionals believe in FEED or LYRA?

Which has better earnings and valuation, FEED or LYRA?

Is FEED or LYRA more profitable?

Does the media prefer FEED or LYRA?

Which has more volatility and risk, FEED or LYRA?

Summary

How does Lyra Therapeutics compare to Tenon Medical?

Do analysts recommend LYRA or TNON?

Which has better earnings & valuation, LYRA or TNON?

Which has more risk and volatility, LYRA or TNON?

Is LYRA or TNON more profitable?

Does the media refer more to LYRA or TNON?

Do insiders & institutionals hold more shares of LYRA or TNON?

Summary

How does Lyra Therapeutics compare to Bone Biologics?

Is LYRA or BBLG more profitable?

Do analysts rate LYRA or BBLG?

Does the media favor LYRA or BBLG?

Which has more risk and volatility, LYRA or BBLG?

Do institutionals and insiders hold more shares of LYRA or BBLG?

Which has higher earnings and valuation, LYRA or BBLG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYRA vs. The Competition

Lyra Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools